{"product_id":"retratrutide-5mg-vial","title":"Retatrutide 10mg vial","description":"\u003cp style=\"text-align: center;\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eNOT FOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"616\" data-start=\"57\"\u003e\u003cstrong\u003eRetatrutide \u003c\/strong\u003eis a once-weekly, acylated \u003cstrong data-end=\"155\" data-start=\"129\"\u003etriple-agonist peptide\u003c\/strong\u003e that activates \u003cstrong data-end=\"209\" data-start=\"171\"\u003eGLP-1, GIP, and glucagon receptors\u003c\/strong\u003e. The GLP-1\/GIP components drive \u003cstrong data-end=\"310\" data-start=\"242\"\u003eappetite suppression, insulinotropic effects, and β-cell support\u003c\/strong\u003e, while the \u003cstrong data-end=\"334\" data-start=\"322\"\u003eglucagon\u003c\/strong\u003ecomponent adds \u003cstrong data-end=\"390\" data-start=\"350\"\u003eenergy-expenditure and fat-oxidation\u003c\/strong\u003e signals and may improve \u003cstrong data-end=\"436\" data-start=\"415\"\u003ehepatic steatosis\u003c\/strong\u003e. In early–mid-stage trials, the tri-agonist profile has produced \u003cstrong data-end=\"556\" data-start=\"502\"\u003eexceptional weight loss and metabolic improvements\u003c\/strong\u003e. Retatrutide is \u003cstrong data-end=\"592\" data-start=\"573\"\u003einvestigational\u003c\/strong\u003e (not FDA\/EMA-approved).\u003c\/p\u003e\n\u003chr data-end=\"621\" data-start=\"618\"\u003e\n\u003ch3 data-end=\"685\" data-start=\"623\"\u003eAdditional Benefits of Retatrutide Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2863\" data-start=\"687\"\u003e\n\u003cthead data-end=\"715\" data-start=\"687\"\u003e\n\u003ctr data-end=\"715\" data-start=\"687\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"697\" data-start=\"687\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"715\" data-start=\"697\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2863\" data-start=\"726\"\u003e\n\u003ctr data-end=\"999\" data-start=\"726\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"760\" data-start=\"726\"\u003e\u003cstrong data-end=\"759\" data-start=\"728\"\u003e1 Unprecedented weight loss\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"999\" data-start=\"760\"\u003ePhase 2 obesity cohorts reported \u003cstrong data-end=\"845\" data-start=\"795\"\u003e~20–25% mean body-weight reduction at 48 weeks\u003c\/strong\u003e on higher doses, with curves still trending down—exceeding typical GLP-1 and even dual GIP\/GLP-1 results. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;New England Journal of Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1247\" data-start=\"1000\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1033\" data-start=\"1000\"\u003e\u003cstrong data-end=\"1032\" data-start=\"1002\"\u003e2 Potent glycaemic control\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1247\" data-start=\"1033\"\u003eIn type 2 diabetes, \u003cstrong data-end=\"1089\" data-start=\"1055\"\u003eA1c reductions approaching ~2%\u003c\/strong\u003e with parallel fasting-glucose and post-prandial improvements; many participants reach \u003cstrong data-end=\"1187\" data-start=\"1176\"\u003eA1c \u0026lt;7%\u003c\/strong\u003e without rescue therapy. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCEM; Diabetes Care\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1512\" data-start=\"1248\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1281\" data-start=\"1248\"\u003e\u003cstrong data-end=\"1280\" data-start=\"1250\"\u003e3 Liver-fat \u0026amp; MASH signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1512\" data-start=\"1281\"\u003eMarked \u003cstrong data-end=\"1312\" data-start=\"1290\"\u003eMRI-PDFF decreases\u003c\/strong\u003e and \u003cstrong data-end=\"1341\" data-start=\"1317\"\u003eALT\/AST improvements\u003c\/strong\u003e suggest meaningful \u003cstrong data-end=\"1375\" data-start=\"1361\"\u003eNAFLD\/MASH\u003c\/strong\u003eactivity, consistent with glucagon-mediated hepatic lipid mobilization plus weight loss. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology; Liver International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1759\" data-start=\"1513\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1550\" data-start=\"1513\"\u003e\u003cstrong data-end=\"1549\" data-start=\"1515\"\u003e4 Cardiometabolic risk profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1759\" data-start=\"1550\"\u003e\n\u003cstrong data-end=\"1594\" data-start=\"1552\"\u003eTriglycerides fall, HDL rises modestly\u003c\/strong\u003e, and \u003cstrong data-end=\"1627\" data-start=\"1600\"\u003enon-HDL\/apoB trend down\u003c\/strong\u003e; \u003cstrong data-end=\"1647\" data-start=\"1629\"\u003eblood pressure\u003c\/strong\u003e often drops \u003cstrong data-end=\"1678\" data-start=\"1660\"\u003e~6–10\/3–5 mmHg\u003c\/strong\u003e with waist-circumference shrinkage. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation; Atherosclerosis\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2029\" data-start=\"1760\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1794\" data-start=\"1760\"\u003e\u003cstrong data-end=\"1793\" data-start=\"1762\"\u003e5 Higher energy expenditure\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2029\" data-start=\"1794\"\u003eHuman calorimetry and preclinical data show \u003cstrong data-end=\"1872\" data-start=\"1840\"\u003e↑ resting energy expenditure\u003c\/strong\u003e and \u003cstrong data-end=\"1894\" data-start=\"1877\"\u003efat oxidation\u003c\/strong\u003e, attributed to glucagon receptor activation—countering adaptive metabolic slowdown. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cell Metabolism; Nature Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2219\" data-start=\"2030\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2053\" data-start=\"2030\"\u003e\u003cstrong data-end=\"2052\" data-start=\"2032\"\u003e6 OSA \u0026amp; mobility\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2219\" data-start=\"2053\"\u003eLarge weight loss translates to \u003cstrong data-end=\"2117\" data-start=\"2087\"\u003eimproved AHI (sleep apnea)\u003c\/strong\u003e and \u003cstrong data-end=\"2157\" data-start=\"2122\"\u003ebetter functional capacity\/pain\u003c\/strong\u003emarkers in obesity substudies. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Chest; Obesity\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2472\" data-start=\"2220\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2265\" data-start=\"2220\"\u003e\u003cstrong data-end=\"2264\" data-start=\"2222\"\u003e7 Early β-cell\/insulin-sparing effects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2472\" data-start=\"2265\"\u003e\n\u003cstrong data-end=\"2288\" data-start=\"2267\"\u003eGIP\/GLP-1 synergy\u003c\/strong\u003e improves \u003cstrong data-end=\"2321\" data-start=\"2298\"\u003efirst-phase insulin\u003c\/strong\u003e and \u003cstrong data-end=\"2355\" data-start=\"2326\"\u003eglucose-dependent control\u003c\/strong\u003e, allowing \u003cstrong data-end=\"2388\" data-start=\"2366\"\u003ede-intensification\u003c\/strong\u003e of other diabetes meds in some participants. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Diabetes; Diabetologia\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2674\" data-start=\"2473\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2520\" data-start=\"2473\"\u003e\u003cstrong data-end=\"2519\" data-start=\"2475\"\u003e8 Visceral-fat and ectopic-fat reduction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2674\" data-start=\"2520\"\u003eImaging (DXA\/MRI) indicates \u003cstrong data-end=\"2599\" data-start=\"2550\"\u003epreferential loss of visceral and hepatic fat\u003c\/strong\u003e, key for cardiometabolic risk modification. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCM; Radiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2863\" data-start=\"2675\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2699\" data-start=\"2675\"\u003e\u003cstrong data-end=\"2698\" data-start=\"2677\"\u003e9 Quality of life\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2863\" data-start=\"2699\"\u003eMeaningful improvements in \u003cstrong data-end=\"2778\" data-start=\"2728\"\u003esatiety, cravings, physical function, and PROs\u003c\/strong\u003e accompany weight\/metabolic change. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Obesity; Quality of Life Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2868\" data-start=\"2865\"\u003e\n\u003ch2 data-end=\"2905\" data-start=\"2870\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2942\" data-start=\"2907\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-end=\"3389\" data-start=\"2943\"\u003e\n\u003cli data-end=\"3047\" data-start=\"2943\"\u003e\n\u003cp data-end=\"3047\" data-start=\"2945\"\u003e\u003cstrong data-end=\"2956\" data-start=\"2945\"\u003eGLP-1R:\u003c\/strong\u003e ↓ appetite, ↓ gastric emptying, ↑ glucose-dependent insulin, ↓ glucagon (post-prandial).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3170\" data-start=\"3048\"\u003e\n\u003cp data-end=\"3170\" data-start=\"3050\"\u003e\u003cstrong data-end=\"3059\" data-start=\"3050\"\u003eGIPR:\u003c\/strong\u003e Amplifies insulin secretion, may enhance \u003cstrong data-end=\"3136\" data-start=\"3101\"\u003eadipocyte metabolic flexibility\u003c\/strong\u003e and GI tolerability with GLP-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3389\" data-start=\"3171\"\u003e\n\u003cp data-end=\"3389\" data-start=\"3173\"\u003e\u003cstrong data-end=\"3193\" data-start=\"3173\"\u003eGCGR (glucagon):\u003c\/strong\u003e ↑ energy expenditure and fat oxidation; \u003cstrong data-end=\"3264\" data-start=\"3234\"\u003ehepatic lipid mobilization\u003c\/strong\u003e and \u003cstrong data-end=\"3287\" data-start=\"3269\"\u003eanti-steatotic\u003c\/strong\u003e effects; modest ↑ hepatic glucose output that is \u003cstrong data-end=\"3357\" data-start=\"3337\"\u003ecounter-balanced\u003c\/strong\u003e by GLP-1\/GIP glycaemic control.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"3418\" data-start=\"3391\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3891\" data-start=\"3420\"\u003e\n\u003cthead data-end=\"3462\" data-start=\"3420\"\u003e\n\u003ctr data-end=\"3462\" data-start=\"3420\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3430\" data-start=\"3420\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3451\" data-start=\"3430\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3462\" data-start=\"3451\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3891\" data-start=\"3477\"\u003e\n\u003ctr data-end=\"3557\" data-start=\"3477\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3508\" data-start=\"3477\"\u003e\u003cstrong data-end=\"3507\" data-start=\"3479\"\u003ePOMC\/AgRP (hypothalamus)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3532\" data-start=\"3508\"\u003eSatiety ↑, cravings ↓\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3557\" data-start=\"3532\"\u003eCNS appetite circuits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3641\" data-start=\"3558\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3582\" data-start=\"3558\"\u003e\u003cstrong data-end=\"3581\" data-start=\"3560\"\u003eIslet (GLP-1\/GIP)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3629\" data-start=\"3582\"\u003eGlucose-dependent insulin ↑, β-cell stress ↓\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3641\" data-start=\"3629\"\u003ePancreas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3724\" data-start=\"3642\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3678\" data-start=\"3642\"\u003e\u003cstrong data-end=\"3677\" data-start=\"3644\"\u003eHepatic lipid handling (GCGR)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3715\" data-start=\"3678\"\u003eTG export\/oxidation ↑, steatosis ↓\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3724\" data-start=\"3715\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3800\" data-start=\"3725\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3751\" data-start=\"3725\"\u003e\u003cstrong data-end=\"3750\" data-start=\"3727\"\u003eBrown\/white adipose\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3782\" data-start=\"3751\"\u003eThermogenesis\/FAO programs ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3800\" data-start=\"3782\"\u003eAdipose tissue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3891\" data-start=\"3801\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3816\" data-start=\"3801\"\u003e\u003cstrong data-end=\"3815\" data-start=\"3803\"\u003eCV-renal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3873\" data-start=\"3816\"\u003eBP ↓, natriuresis signals ↑ (weight-mediated + direct)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3891\" data-start=\"3873\"\u003eVascular\/renal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3896\" data-start=\"3893\"\u003e\n\u003ch2 data-end=\"3920\" data-start=\"3898\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4330\" data-start=\"3922\"\u003e\n\u003cli data-end=\"4014\" data-start=\"3922\"\u003e\n\u003cp data-end=\"4014\" data-start=\"3924\"\u003e\u003cstrong data-end=\"3934\" data-start=\"3924\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-end=\"3963\" data-start=\"3935\"\u003eOnce-weekly SC injection\u003c\/strong\u003e with dose-escalation to improve GI tolerability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4119\" data-start=\"4015\"\u003e\n\u003cp data-end=\"4119\" data-start=\"4017\"\u003e\u003cstrong data-end=\"4042\" data-start=\"4017\"\u003eAbsorption\/half-life:\u003c\/strong\u003e Engineered for \u003cstrong data-end=\"4091\" data-start=\"4058\"\u003emulti-day half-life (~1 week)\u003c\/strong\u003e supporting weekly dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4267\" data-start=\"4120\"\u003e\n\u003cp data-end=\"4267\" data-start=\"4122\"\u003e\u003cstrong data-end=\"4149\" data-start=\"4122\"\u003eDistribution\/clearance:\u003c\/strong\u003e Albumin-binding\/acylation prolong exposure; peptide catabolism via proteases; renal\/hepatic clearance of fragments.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4330\" data-start=\"4268\"\u003e\n\u003cp data-end=\"4330\" data-start=\"4270\"\u003e\u003cstrong data-end=\"4292\" data-start=\"4270\"\u003eFood interactions:\u003c\/strong\u003e Not clinically relevant (injected).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4335\" data-start=\"4332\"\u003e\n\u003ch2 data-end=\"4377\" data-start=\"4337\"\u003e4. Pre-clinical and Clinical Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4415\" data-start=\"4379\"\u003e4.1 Obesity (without diabetes)\u003c\/h3\u003e\n\u003cp data-end=\"4637\" data-start=\"4416\"\u003eDose-ranging Phase 2 showed \u003cstrong data-end=\"4481\" data-start=\"4444\"\u003elarge, dose-dependent weight loss\u003c\/strong\u003e through 48 weeks, with a majority of participants achieving \u003cstrong data-end=\"4550\" data-start=\"4542\"\u003e≥15%\u003c\/strong\u003e and many \u003cstrong data-end=\"4568\" data-start=\"4560\"\u003e≥20%\u003c\/strong\u003e loss. Trajectories suggested additional loss with continued therapy.\u003c\/p\u003e\n\u003ch3 data-end=\"4664\" data-start=\"4639\"\u003e4.2 Type 2 Diabetes\u003c\/h3\u003e\n\u003cp data-end=\"4899\" data-start=\"4665\"\u003eRetatrutide produced \u003cstrong data-end=\"4722\" data-start=\"4686\"\u003erobust A1c and weight reductions\u003c\/strong\u003e vs placebo\/active comparators, improving fasting\/post-prandial glucose, time-in-range (CGM), lipids, and BP. Hypoglycaemia was \u003cstrong data-end=\"4862\" data-start=\"4850\"\u003euncommon\u003c\/strong\u003e outside insulin\/sulfonylurea co-use.\u003c\/p\u003e\n\u003ch3 data-end=\"4921\" data-start=\"4901\"\u003e4.3 NAFLD\/MASH\u003c\/h3\u003e\n\u003cp data-end=\"5101\" data-start=\"4922\"\u003eMeaningful \u003cstrong data-end=\"4956\" data-start=\"4933\"\u003eMRI-PDFF reductions\u003c\/strong\u003e and enzyme improvements occurred early, consistent with \u003cstrong data-end=\"5060\" data-start=\"5013\"\u003edual weight-dependent and glucagon-mediated\u003c\/strong\u003e effects; histology programs are ongoing.\u003c\/p\u003e\n\u003cblockquote data-end=\"5339\" data-start=\"5103\"\u003e\n\u003cp data-end=\"5339\" data-start=\"5105\"\u003e\u003cstrong data-end=\"5131\" data-start=\"5105\"\u003eEvidence quality note:\u003c\/strong\u003e Data to date are \u003cstrong data-end=\"5160\" data-start=\"5149\"\u003ePhase 2\u003c\/strong\u003e (plus expanding Phase 3 programs). Magnitudes above are representative of published results; long-term outcomes (CV events, MASH histology, hard renal endpoints) are \u003cstrong data-end=\"5338\" data-start=\"5327\"\u003epending\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5344\" data-start=\"5341\"\u003e\n\u003ch2 data-end=\"5379\" data-start=\"5346\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5879\" data-start=\"5381\"\u003e\n\u003cthead data-end=\"5411\" data-start=\"5381\"\u003e\n\u003ctr data-end=\"5411\" data-start=\"5381\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5389\" data-start=\"5381\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5401\" data-start=\"5389\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5411\" data-start=\"5401\"\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5879\" data-start=\"5426\"\u003e\n\u003ctr data-end=\"5503\" data-start=\"5426\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5459\" data-start=\"5426\"\u003e\u003cstrong data-end=\"5458\" data-start=\"5428\"\u003eObesity (broad BMI ranges)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5492\" data-start=\"5459\"\u003eSuperior weight loss potential\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5503\" data-start=\"5492\"\u003ePhase 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5584\" data-start=\"5504\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5541\" data-start=\"5504\"\u003e\u003cstrong data-end=\"5540\" data-start=\"5506\"\u003eT2D (mono\/combination therapy)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5571\" data-start=\"5541\"\u003eStrong A1c + weight effects\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5584\" data-start=\"5571\"\u003ePhase 2→3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5654\" data-start=\"5585\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5602\" data-start=\"5585\"\u003e\u003cstrong data-end=\"5601\" data-start=\"5587\"\u003eMASH\/NAFLD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5636\" data-start=\"5602\"\u003eLiver-fat and fibrosis pathways\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5654\" data-start=\"5636\"\u003eOngoing trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5712\" data-start=\"5655\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5665\" data-start=\"5655\"\u003e\u003cstrong data-end=\"5664\" data-start=\"5657\"\u003eOSA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5697\" data-start=\"5665\"\u003eWeight-linked AHI improvement\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5712\" data-start=\"5697\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5786\" data-start=\"5713\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5738\" data-start=\"5713\"\u003e\u003cstrong data-end=\"5737\" data-start=\"5715\"\u003eHFpEF with obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5775\" data-start=\"5738\"\u003eWeight\/BP\/VO₂ \u0026amp; congestion signals\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5786\" data-start=\"5775\"\u003eConcept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5879\" data-start=\"5787\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5817\" data-start=\"5787\"\u003e\u003cstrong data-end=\"5816\" data-start=\"5789\"\u003ePCOS\/metabolic syndrome\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5864\" data-start=\"5817\"\u003eWeight, insulin resistance, ovulatory milieu\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5879\" data-start=\"5864\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5884\" data-start=\"5881\"\u003e\n\u003ch2 data-end=\"5915\" data-start=\"5886\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"7000\" data-start=\"5917\"\u003e\n\u003cli data-end=\"6108\" data-start=\"5917\"\u003e\n\u003cp data-end=\"6108\" data-start=\"5919\"\u003e\u003cstrong data-end=\"5962\" data-start=\"5919\"\u003eCommon (dose-related, typically early):\u003c\/strong\u003e \u003cstrong data-end=\"6022\" data-start=\"5963\"\u003eNausea, vomiting, diarrhea\/constipation, abdominal pain\u003c\/strong\u003e, \u003cstrong data-end=\"6056\" data-start=\"6024\"\u003etransient decreased appetite\u003c\/strong\u003e; generally manageable with \u003cstrong data-end=\"6105\" data-start=\"6084\"\u003egradual titration\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6234\" data-start=\"6109\"\u003e\n\u003cp data-end=\"6234\" data-start=\"6111\"\u003e\u003cstrong data-end=\"6127\" data-start=\"6111\"\u003eVitals\/labs:\u003c\/strong\u003e \u003cstrong data-end=\"6150\" data-start=\"6128\"\u003eModest HR increase\u003c\/strong\u003e (few bpm); \u003cstrong data-end=\"6178\" data-start=\"6162\"\u003eBP decreases\u003c\/strong\u003e; \u003cstrong data-end=\"6191\" data-start=\"6180\"\u003eALT\/AST\u003c\/strong\u003e usually fall with weight\/liver-fat loss.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6343\" data-start=\"6235\"\u003e\n\u003cp data-end=\"6343\" data-start=\"6237\"\u003e\u003cstrong data-end=\"6253\" data-start=\"6237\"\u003eGallbladder:\u003c\/strong\u003e Risk of \u003cstrong data-end=\"6294\" data-start=\"6262\"\u003echolelithiasis\/cholecystitis\u003c\/strong\u003e rises with rapid weight loss—monitor symptoms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6430\" data-start=\"6344\"\u003e\n\u003cp data-end=\"6430\" data-start=\"6346\"\u003e\u003cstrong data-end=\"6359\" data-start=\"6346\"\u003ePancreas:\u003c\/strong\u003e \u003cstrong data-end=\"6376\" data-start=\"6360\"\u003ePancreatitis\u003c\/strong\u003e is rare; counsel on symptoms and stop if suspected.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6544\" data-start=\"6431\"\u003e\n\u003cp data-end=\"6544\" data-start=\"6433\"\u003e\u003cstrong data-end=\"6449\" data-start=\"6433\"\u003eGI motility:\u003c\/strong\u003e \u003cstrong data-end=\"6483\" data-start=\"6450\"\u003eGastroparesis\/aspiration risk\u003c\/strong\u003e around anesthesia—follow peri-procedural fasting guidance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6659\" data-start=\"6545\"\u003e\n\u003cp data-end=\"6659\" data-start=\"6547\"\u003e\u003cstrong data-end=\"6565\" data-start=\"6547\"\u003eHypoglycaemia:\u003c\/strong\u003e Uncommon without insulin\/secretagogues; adjust those doses as weight and glycaemia improve.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6848\" data-start=\"6660\"\u003e\n\u003cp data-end=\"6848\" data-start=\"6662\"\u003e\u003cstrong data-end=\"6704\" data-start=\"6662\"\u003eThyroid C-cell warning (class\/rodent):\u003c\/strong\u003e GLP-1–based agents carry a \u003cstrong data-end=\"6762\" data-start=\"6732\"\u003erodent C-cell tumor signal\u003c\/strong\u003e; \u003cstrong data-end=\"6817\" data-start=\"6764\"\u003eavoid with personal\/family history of MTC or MEN2\u003c\/strong\u003e pending specific label data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7000\" data-start=\"6849\"\u003e\n\u003cp data-end=\"7000\" data-start=\"6851\"\u003e\u003cstrong data-end=\"6881\" data-start=\"6851\"\u003eContraindications\/caution:\u003c\/strong\u003e Pregnancy\/breastfeeding, severe GI disease, active gallbladder disease, pancreatitis history—use specialist judgement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"7031\" data-start=\"7002\"\u003e\u003cstrong data-end=\"7031\" data-start=\"7002\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7609\" data-start=\"7033\"\u003e\n\u003cthead data-end=\"7135\" data-start=\"7033\"\u003e\n\u003ctr data-end=\"7135\" data-start=\"7033\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7043\" data-start=\"7033\"\u003eFeature\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"7078\" data-start=\"7043\"\u003e\u003cstrong data-end=\"7077\" data-start=\"7045\"\u003eRetatrutide (GLP-1\/GIP\/GCGR)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7108\" data-start=\"7078\"\u003e\u003cstrong data-end=\"7107\" data-start=\"7080\"\u003eTirzepatide (GLP-1\/GIP)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"7135\" data-start=\"7108\"\u003e\u003cstrong data-end=\"7133\" data-start=\"7110\"\u003eSemaglutide (GLP-1)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7609\" data-start=\"7154\"\u003e\n\u003ctr data-end=\"7274\" data-start=\"7154\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7180\" data-start=\"7154\"\u003eWeight loss (48–72 wks)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7231\" data-start=\"7180\"\u003e\n\u003cstrong data-end=\"7195\" data-start=\"7182\"\u003eVery high\u003c\/strong\u003e (≥20% avg at upper doses, Phase 2)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7252\" data-start=\"7231\"\u003e\n\u003cstrong data-end=\"7241\" data-start=\"7233\"\u003eHigh\u003c\/strong\u003e (≈15–22%)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7274\" data-start=\"7252\"\u003e\n\u003cstrong data-end=\"7262\" data-start=\"7254\"\u003eHigh\u003c\/strong\u003e (≈12–17%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7335\" data-start=\"7275\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7290\" data-start=\"7275\"\u003eA1c lowering\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7306\" data-start=\"7290\"\u003e\n\u003cstrong data-end=\"7299\" data-start=\"7292\"\u003e~2%\u003c\/strong\u003e (T2D)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7320\" data-start=\"7306\"\u003e\u003cstrong data-end=\"7319\" data-start=\"7308\"\u003e~2–2.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7335\" data-start=\"7320\"\u003e\u003cstrong data-end=\"7333\" data-start=\"7322\"\u003e~1.5–2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7402\" data-start=\"7336\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7357\" data-start=\"7336\"\u003eEnergy expenditure\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7376\" data-start=\"7357\"\u003e\u003cstrong data-end=\"7375\" data-start=\"7359\"\u003e↑ (glucagon)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7391\" data-start=\"7376\"\u003eNeutral–mild\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7402\" data-start=\"7391\"\u003eNeutral\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7502\" data-start=\"7403\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7421\" data-start=\"7403\"\u003eGI tolerability\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7449\" data-start=\"7421\"\u003eGLP-1-like; titration key\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7487\" data-start=\"7449\"\u003eGLP-1-like; improved vs GLP-1 alone\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7502\" data-start=\"7487\"\u003eGLP-1-class\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7555\" data-start=\"7503\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7511\" data-start=\"7503\"\u003eHR\/BP\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7534\" data-start=\"7511\"\u003eHR ↑ small; \u003cstrong data-end=\"7533\" data-start=\"7525\"\u003eBP ↓\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7544\" data-start=\"7534\"\u003eSimilar\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7555\" data-start=\"7544\"\u003eSimilar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7609\" data-start=\"7556\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7569\" data-start=\"7556\"\u003eNAFLD\/MASH\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"7590\" data-start=\"7569\"\u003e\u003cstrong data-end=\"7589\" data-start=\"7571\"\u003eStrong signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7599\" data-start=\"7590\"\u003eStrong\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7609\" data-start=\"7599\"\u003eStrong\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7614\" data-start=\"7611\"\u003e\n\u003ch2 data-end=\"7642\" data-start=\"7616\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7946\" data-start=\"7644\"\u003e\n\u003cli data-end=\"7725\" data-start=\"7644\"\u003e\n\u003cp data-end=\"7725\" data-start=\"7646\"\u003e\u003cstrong data-end=\"7666\" data-start=\"7646\"\u003eApproval status:\u003c\/strong\u003e \u003cstrong data-end=\"7686\" data-start=\"7667\"\u003eInvestigational\u003c\/strong\u003e; \u003cstrong data-end=\"7718\" data-start=\"7688\"\u003eno marketing authorization\u003c\/strong\u003e yet.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7834\" data-start=\"7726\"\u003e\n\u003cp data-end=\"7834\" data-start=\"7728\"\u003e\u003cstrong data-end=\"7741\" data-start=\"7728\"\u003ePrograms:\u003c\/strong\u003e Late-phase \u003cstrong data-end=\"7777\" data-start=\"7753\"\u003eobesity and diabetes\u003c\/strong\u003e trials underway; \u003cstrong data-end=\"7812\" data-start=\"7795\"\u003eliver-disease\u003c\/strong\u003e programs expanding.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7946\" data-start=\"7835\"\u003e\n\u003cp data-end=\"7946\" data-start=\"7837\"\u003e\u003cstrong data-end=\"7860\" data-start=\"7837\"\u003eUse outside trials:\u003c\/strong\u003e Not recommended; compounded “tri-agonists” are \u003cstrong data-end=\"7915\" data-start=\"7908\"\u003enot\u003c\/strong\u003e equivalent to GMP retatrutide.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7951\" data-start=\"7948\"\u003e\n\u003ch2 data-end=\"7976\" data-start=\"7953\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8580\" data-start=\"7978\"\u003e\n\u003cli data-end=\"8075\" data-start=\"7978\"\u003e\n\u003cp data-end=\"8075\" data-start=\"7980\"\u003e\u003cstrong data-end=\"8020\" data-start=\"7980\"\u003eCardiovascular-outcomes trial (CVOT)\u003c\/strong\u003e to quantify \u003cstrong data-end=\"8051\" data-start=\"8033\"\u003eMACE reduction\u003c\/strong\u003e and renal protection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8150\" data-start=\"8076\"\u003e\n\u003cp data-end=\"8150\" data-start=\"8078\"\u003e\u003cstrong data-end=\"8109\" data-start=\"8078\"\u003eHistology-based MASH trials\u003c\/strong\u003e (NASH resolution, fibrosis endpoints).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8261\" data-start=\"8151\"\u003e\n\u003cp data-end=\"8261\" data-start=\"8153\"\u003e\u003cstrong data-end=\"8184\" data-start=\"8153\"\u003eBody-composition \u0026amp; function\u003c\/strong\u003e: DXA\/MRI (visceral\/ectopic fat, lean-mass preservation), \u003cstrong data-end=\"8258\" data-start=\"8242\"\u003estrength\/VO₂\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8354\" data-start=\"8262\"\u003e\n\u003cp data-end=\"8354\" data-start=\"8264\"\u003e\u003cstrong data-end=\"8298\" data-start=\"8264\"\u003eDose-finding\/titration science\u003c\/strong\u003e to balance maximal efficacy with \u003cstrong data-end=\"8351\" data-start=\"8332\"\u003eGI tolerability\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8491\" data-start=\"8355\"\u003e\n\u003cp data-end=\"8491\" data-start=\"8357\"\u003e\u003cstrong data-end=\"8383\" data-start=\"8357\"\u003eCombination strategies\u003c\/strong\u003e (e.g., \u003cstrong data-end=\"8402\" data-start=\"8391\"\u003estatins\u003c\/strong\u003e, \u003cstrong data-end=\"8424\" data-start=\"8404\"\u003eSGLT2 inhibitors\u003c\/strong\u003e) and \u003cstrong data-end=\"8449\" data-start=\"8430\"\u003eperi-procedural\u003c\/strong\u003e protocols (aspiration risk mitigation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8580\" data-start=\"8492\"\u003e\n\u003cp data-end=\"8580\" data-start=\"8494\"\u003e\u003cstrong data-end=\"8523\" data-start=\"8494\"\u003ePatient-reported outcomes\u003c\/strong\u003e on satiety, cravings, and QoL to guide shared decisions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8585\" data-start=\"8582\"\u003e\n\u003ch3 data-end=\"8610\" data-start=\"8587\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"9272\" data-start=\"8612\"\u003e\n\u003cli data-end=\"8733\" data-start=\"8612\"\u003e\n\u003cp data-end=\"8733\" data-start=\"8614\"\u003e\u003cstrong data-end=\"8649\" data-start=\"8614\"\u003eNew England Journal of Medicine\u003c\/strong\u003e — Phase 2 retatrutide in obesity: magnitude of weight loss and metabolic effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8840\" data-start=\"8734\"\u003e\n\u003cp data-end=\"8840\" data-start=\"8736\"\u003e\u003cstrong data-end=\"8759\" data-start=\"8736\"\u003eDiabetes Care; JCEM\u003c\/strong\u003e — Glycaemic efficacy and β-cell physiology with incretin\/glucagon tri-agonism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8940\" data-start=\"8841\"\u003e\n\u003cp data-end=\"8940\" data-start=\"8843\"\u003e\u003cstrong data-end=\"8878\" data-start=\"8843\"\u003eHepatology; Liver International\u003c\/strong\u003e — Incretin\/glucagon pathways in hepatic steatosis and MASH.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9055\" data-start=\"8941\"\u003e\n\u003cp data-end=\"9055\" data-start=\"8943\"\u003e\u003cstrong data-end=\"8981\" data-start=\"8943\"\u003eCell Metabolism; Nature Metabolism\u003c\/strong\u003e — Mechanistic work on tri-agonists (energy expenditure, fat oxidation).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9150\" data-start=\"9056\"\u003e\n\u003cp data-end=\"9150\" data-start=\"9058\"\u003e\u003cstrong data-end=\"9090\" data-start=\"9058\"\u003eCirculation; Atherosclerosis\u003c\/strong\u003e — Cardiometabolic risk-factor changes (BP, lipids, apoB).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"9272\" data-start=\"9151\"\u003e\n\u003cp data-end=\"9272\" data-start=\"9153\"\u003e\u003cstrong data-end=\"9197\" data-start=\"9153\"\u003eObesity; Quality of Life Research; Chest\u003c\/strong\u003e — PROs, functional outcomes, and OSA signals with substantial weight loss\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684871270738,"sku":"10","price":65.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/retatrutide.png?v=1770834975","url":"https:\/\/sciencepeptideslab.com\/products\/retratrutide-5mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}